A MicroRNA Panel in Pancreatic Cyst Fluid for the Risk Stratification of Pancreatic Cysts in a Prospective Cohort

WK Utomo1, LH Looijenga2, MJ Bruno1, BE Hansen1, AJM Gillis2, K Bierrmann2, MP Peppelenbosch1, GM Fuhler1 and H Braat1

A subset of pancreatic cystic neoplasms are regarded as precursor lesions of pancreatic cancer, but only a minority of all pancreatic cystic neoplasms will undergo malignant transformation. MicroRNAs are increasingly recognized as molecular targets in carcinogenesis. Previously, a 9-microRNA (miR) signature was suggested to discriminate between high and low risk pancreatic cystic neoplasm. In this study, we aimed to validate this 9-miR panel in a prospective cohort. Total miR was isolated from pancreatic cyst fluid and expression of miR18a, miR24, miR30a-3p, miR92a, miR99b, miR106b, miR142-3p, miR342-3p, and miR532-3p was analyzed by singleplex Taqman MicroRNA Assay. A total of 62 patient samples were analyzed. During follow-up, 24 (38.7%) patients underwent resection, of which 6 (9.7%) patients showed at least high grade dysplasia. A logistic regression model presented a “predicted risk” score which significantly differed between low and high risk cysts, either including all patients or only those with histological confirmation of diagnosis. Using a set cut-off of 50%, the sensitivity of the model for the total cohort was 10.0%, specificity 100.0%, positive predicted value 100.0%, negative predicted value 85.2%, and diagnostic accuracy of 85.5%. Thus, while observing a significant difference between low and high risk cysts, clinical implementation of this biomarker panel is as yet unlikely to be beneficial in the management of pancreatic cysts.

Molecular Therapy—Nucleic Acids (2016) 5, e350; doi:10.1038/mtna.2016.61; published online 16 August 2016

Subject Category: siRNAs, shRNAs and MiRNAs

Introduction

Pancreatic Cystic Neoplasms (PCNs) are potential precursors of pancreatic cancer.1 With the widespread use of radiologic cross-sectional imaging, PCNs are discovered with increasing frequency. The prevalence of pancreatic cysts in patients undergoing cross-sectional imaging of the abdomen is estimated to be ~2.4%.2 Patients with a PCN have been shown to have a 35 times higher age- and gender-adjusted incidence of pancreatic malignancy compared with a noncyst population.1 Therefore, PCNs are generally regarded as premalignant lesions and preemptive resections are often considered necessary.

Surgical treatment of cysts varies from pancreaticoduodenectomy to distal pancreatectomy with or without splenectomy. These invasive procedures are associated with a significant risk of morbidity and mortality, which may be unnecessary when the cyst has little to no malignant potential. In the past, some studies showed that half of the pancreatic cysts resected turned out histopathologically to be a pseudocyst, while the remainder consisted of true PCNs of various origins and dysplastic grade.3 In recent years, diagnostic performance has improved considerably, but nevertheless there is need for better identification of cysts with malignant potential. Studies validating the initial criteria for resection of PCN (i.e., Sendai guidelines3) have shown a high sensitivity, close to 100%, but very low specificity of 25–30%. The revised guidelines released in 2012 (Fukuoka guidelines4) appear to perform better, but nevertheless, have shown that 67.7% of resected patients are still exposed to unnecessary surgery for cysts which in hindsight were low risk PCN.8 Thus, there is an urgent need for additional predictors to aid in the clinical decision making whether to operate or not.

Endoscopic ultrasound (EUS) is considered a valuable asset to aid in the differentiation between various pancreatic cysts including intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasms, however, it unfortunately does not allow reliable identification of the presence and/or risk of malignant transformation other than the identification of nonspecific morphological features like mural nodules or asymmetric cyst wall thickening. Unfortunately, there is a poor correlation between morphological features and dysplastic grade. Biomarkers such as carcinoembryonic antigen, while able to help distinguish between mucinous and nonmucinous cysts, have shown limited sensitivity and specificity for diagnosis and prognosis of pancreatic cancer.9–12 Several other markers have been investigated, including carbohydrate antigen 19-9, although, again, poor sensitivity and specificity preclude the use of this marker for pancreatic cancer diagnosis.13

Currently, there is an increasing interest in the potential use of pancreatic cyst fluid in the treatment algorithm of patients with pancreatic cysts. Cyst fluid obtained by EUS-fine needle aspiration (EUS-FNA) may contain precancerous cells which potentially can be identified by mutational status analysis. KRAS mutations are common in pancreatic cancer and the largest study to date investigating the use of KRAS mutation detection in pancreatic cyst fluids was the pancreatic cyst DNA analysis (PANDA) study.14 They showed that while KRAS mutations were more prevalent...
in mucinous cysts, the presence of KRAS mutations did not distinguish premalignant from malignant cysts, and while additional allelic loss was highly specific for malignant cysts (96%), sensitivity was low (37%). However, next generation sequencing may improve sensitivity, and combining molecular markers (i.e., BRAF, CDKN2A, CTNNB1, GNAS, KRAS, NRAS, PIK3CA, RNF43, SMAD4, TP53, and VHL and loss of heterozygosity thereof) together with clinical markers may improve diagnostic accuracy of PCN.15–17

Biomolecules released by dysplastic cells may also be present in cyst fluid, and may aid in the identification of premalignant cysts. One such potential biomarker is the presence of miRs in pancreatic cyst fluid, which could be differentially expressed in benign, dysplastic, and malignant cysts.

MicroRNAs (MiRs) are small, noncoding, functional RNAs of ~21–23 nucleotides in length that are involved in epigenetic regulation by binding to specific mRNAs, leading to their degradation and translational repression.18 It has been shown that expression levels of miRs differ between various pathological conditions, including cancer.19 Furthermore, miRs can be quantified in several types of bodily fluids and are extremely stable, showing resistance against their degradation and translational repression.21 In 2012, Matthaei et al. published a 9-miR model, which showed that a panel of nine miRs measured in pancreatic cyst fluid were able to differentiate between low risk cysts and high risk cysts, which allowed stratification of patients into those eligible for either surgery or watchful waiting with a sensitivity of 89%, specificity of 100%, and area under the curve of 1.22 However, clinical implementation of these promising results requires validation. Hence, in this study, we aimed to prospectively validate this 9-miR model in a cohort of pancreatic cyst patients.

**Results**

**Descriptives**

In total, 92 pancreatic cyst fluid samples were collected during the study period. Of those, 12 samples were excluded due to technical difficulties during isolation or inconclusive diagnosis. Samples were spiked with a known concentration of the nonhuman miRNA cel-miR39 in order to confirm efficient isolation of miRs from the sample. In three cases, levels of cel-miR39 after isolation were too low (Ct >30) to assure efficient miR isolation, and samples were discarded (see Supplementary Figure S1). Finally, unreliable measurement of one of the miRs in the panel occurred in 15 samples. Final analysis was performed in 62 patients — see Figure 1 for the flowchart of the study and Table 1 for the clinical patient characteristics. In total, 52 patients with a low risk cyst were included, versus 10 patients with a high risk cyst. Histological confirmation of diagnosis was available through EUS-FNA for 11 patients (17.8%) and by histology after surgery for 24 (38.7%) of which, 25% (6 out of 24) had high grade dysplasia or invasive carcinoma. The remainder of the patients (27; 43.5%) was followed up for a mean duration of 26.59 (0–74.25) months, and for all patients diagnosis known at the end of the follow-up was used.

**Table 1 Patient characteristics of the cohort**

| Diagnosis, n (%) | Total (n = 92) | Low risk cyst (n = 52) | High risk PCN (n = 10) |
|------------------|---------------|-----------------------|-----------------------|
| Age, years       |               |                       |                       |
| Range            | 18–79.5       | 19–79.5               | 45.5–78.4             |
| Mean (SD)        | 58.6 (13.4)   | 58.5 (13.7)           | 65.5 (10.6)           |
| Diagnosis, n (%) |               |                       |                       |
| Mean Branch IPMN | 3 (4.8)       | 1 (1.9)               | 2 (20.0)              |
| Side Branch IPMN | 18 (29.0)     | 16 (30.8)             | 2 (20.0)              |
| Mixed Type IPMN  | 4 (6.5)       | 0 (0)                 | 4 (40.0)              |
| Mucinous Cystic Neoplasm | 13 (21.0) | 11 (21.2) | 2 (20.0) |
| Serous Cystadenoma | 15 (24.2) | 15 (28.8) | 0 (0) |
| Pseudocyst        | 9 (14.5)      | 9 (17.3)              | 0 (0)                 |
| Histological confirmation, n (%) |               |                       |                       |
| None             | 27 (43.5)     | 23 (44.2)             | 4 (40.0)              |
| EUS-FNA          | 11 (17.8)     | 11 (21.2)             | 0 (0)                 |
| Surgery          | 24 (38.7)     | 18 (34.6)             | 6 (60.0)              |
| Dysplasia, of resected (n = 24) |             |                       |                       |
| No dysplasia     | 6 (25.0)      |                       |                       |
| Low grade dysplasia | 9 (37.5)     |                       |                       |
| Moderate grade dysplasia | 3 (12.5) |                       |                       |
| High grade dysplasia | 5 (20.8) |                       |                       |
| Invasive carcinoma | 1 (4.2) |                       |                       |

PCN, pancreatic cystic neoplasms; EUS-FNA, endoscopic ultrasound-fine needle aspiration; IPMN, intraductal papillary mucinous neoplasm.
Validation of a 9-microRNA Panel in Pancreatic Cysts
Utomo et al.

Individual miRs and calculated diffpairs show no significant difference between low risk cysts and high risk cysts
In total, nine miRNA expression levels were measured. Comparing the total expression of these individual miRs did not show significant differences in mean Ct values between low risk and high risk cysts (Figure 2). MiR expression levels were subsequently normalized by making seven distinct “diffpairs” (i.e., seven combinations of two miRNAs), where values were generated by comparing the expression levels of the two miRNAs in that diffpair. The choice of miRNA pairing was based on earlier results by Matthaei et al., who defined these diffpairs based on the most differentially expressed diffpairs used in a L1-penalized logistic regression model (miR18 was combined with miR92a, miR24 with miR30a-3p, miR30a-3p with miR532-3p, miR24 with miR99b, miR106b with miR92a, miR142-3p with miR92a, and miR24 with miR342-3p). One of these diffpair combination (diffpair (miR106b;miR92a)) was found to be significantly different between low risk cysts and high risk cysts (Figure 3). This difference did not hold up in the logistic regression and was therefore considered not clinically relevant. Of note, generating other diffpairs also did not result in significant differences in diffpairs observed between high risk and low risk cysts (see Supplementary Table S1).

The logistic regression model using diffpairs is significantly different between low risk cysts and high risk cysts
The diffpairs were entered in a logistic regression model using previously published regression coefficients.22 The regression coefficient represents the weight given to each diffpair in the model, i.e., in this weighted model each diffpair does not contribute equally to the equation. Diffpair (miR24;miR30a-3p) and diffpair (miR18a;miR92a) contributed the most in this model (see Supplementary Table S2). Exploring the possibility for recalibration did not lead to improved discrimination between low risk and high risk cysts (data not shown). The diffpairs in the logistic regression model together generate a risk score (named the “predicted risk” (13)) which ranges from 0% and 100%. The mean predicted risk was 13.97% for low risk cysts versus 27.3% in the high risk cysts (Figure 4; \( P = 0.013 \)). Comparing high risk IPMN to either low risk IPMN alone or low risk mucinous cystic neoplasms alone also showed significant higher predicted risk in the high risk IPMN (\( P = 0.0286 \) and 0.0093, respectively; Supplementary Figure S2). The diagnostic performance of the logistic regression model classified as fair in separating low risk cysts from high risk cysts, with an area under the receiver operator curve of 0.75 (Figure 5a). Excluding all cases without a histological confirmation, the diagnostic performance increased to good discrimination with an area under the receiver operator characteristic curve of 0.83 (Figure 5b). These data demonstrate that the 9-miR panel shows potential for distinguishing high risk and low risk cysts.

The established cut-off value of 50% is not clinically implementable
Reliable implementation of a diagnostic tool requires reliable cut-off levels with sufficient sensitivity and specificity. From the coordinates of the receiver operator characteristic curve, we explored various cut-off values and evaluated diagnostic
Validation of a 9-microRNA Panel in Pancreatic Cysts
Utomo et al.

characteristics of each of these cut-off points (Table 2). First we employed a cut-off value of 50%, as this was the value suggested in the study of Matthaei et al.22 In our study, a cut-off of 50% yielded a sensitivity of 10.0%, specificity of 100.0%, positive predicted value of 100.0%, negative predicted value of 85.5%, and diagnostic accuracy of 85.5%, which was significantly poorer than the previously reported results. In our study, the optimal cut-off value was 25.66%, as determined by the sensitivity and specificity curve using Graphpad Prism 5 (version 5.01) (Figure 6a), and confirmed using an online cut-off calculator tool. The diagnostic characteristics of the optimal cut-off were 60.0% sensitivity, 90.4% specificity, 54.5% positive predicted value, 92.2% negative predicted value, and 85.5% diagnostic accuracy (Table 2). Only taking samples with the golden standard into account yielded an optimal cut-off value of 25.0% (Figure 6b) which results in a sensitivity of 66.7%, specificity of 89.7%, positive predicted value 57.1%, negative predicted value 92.9%, and diagnostic accuracy of 85.7% (Table 3).

Discussion

With the growing detection of pancreatic cysts of various sizes, it is becoming increasingly important to discriminate between harmless cystic lesions and cysts that have high malignant potential. We prospectively validated a promising 9-miR panel as biomarker for the detection of high risk cysts which should be resected based on the dysplastic transformation within the epithelial lining.22 While in our study we observed a significant difference between low risk cysts and high risk cysts in the predicted risk of the 9-miR model, the threshold of 50% as proposed by Matthaei et al. does not unequivocally segregate low risk from high risk cysts and is accompanied by a very low sensitivity of 10%.

Recently published guidelines of the American Gastroenterological Association regarding asymptomatic cysts have led to a major debate regarding the implementation of these guidelines.23–26 Nine out of ten recommendations for surgery were deemed to be based on very low quality evidence,23 underlining the necessity for a more objective measurement in patients with this increasingly frequent lesion. The importance of finding and validating novel biomarkers for identification of high risk cysts is further emphasized by the high rate of resections performed for low risk PCN (specifically in mucinous cystic neoplasms and side branch-IPMN).8

Figure 4 Graph depicting the predicted probability for resection. The predicted probability is significantly higher in the high risk cyst group (P = 0.013). In the paper published by Matthaei et al., a threshold of 50% (dotted line) was used to determine the need for resection. Error bars denote the 95% confidence interval.

Figure 5 Receiver operator characteristic (ROC) curve of the logistic regression model in predicting cysts that require resection. (a) ROC of the whole cohort. (b) ROC excluding samples without histologic confirmation.
MiRs are being widely investigated as a biomarker for the early detection, diagnosis, prognosis, and treatment response of numerous cancers. The field is rapidly evolving and the first phase 1 trial using a miRNA mimic in liver cancer is currently ongoing.27 As a biomarker, they hold several advantages — e.g., they are very stable and thus measurable across different tissues and different moments in time. Furthermore, miR signatures have been shown to be specifically associated with various types of cancer.28 Most importantly, it is assumed that distinct miRs are released by tumor cells into their environment, and make their way to the periphery, thereby making it possible to measure them in for example blood samples and reducing the need for invasive procedures. The downside to this approach is that circulating miR levels can be sensitive to subtle changes in the human body, including diet and viral infections, leading to conflicting results.29,30 Moreover, the optimal compartment of blood (whole blood, serum, or plasma) in which miRNAs should be measured is still matter of discussion.31

A multitude of circulating miRs has been associated with the detection of pancreatic ductal adenocarcinoma.32–34 These studies, however, generally show considerable dissimilarities in reported miRNAs.36 The use of serum miRs for pancreatic lesion distinction has been described, albeit in a low number of cases, and could be hampered by the fact that the cyst is a closed compartment.36 This may impede the dispersion of molecular markers in the circulation. Using pancreatic cyst fluid as the source for miR measurements may overcome this problem. Several studies have indicated that the use of miRs as a biomarker for malignant degeneration of pancreatic cysts may show promise.22,37,38 However, similar to the problems in circulating miRs, there is no consensus in the best endogenous control for the normalization in pancreatic cyst fluid. Two of these studies have chosen the small nucleolar RNA, RNU6B, as their endogenous control. However, the use of RNU6B for expression normalization has been reported to result in bias and erroneous findings, as they are not stably expressed in all tissues and fluids.39–42 The study by Matthaei et al. was unique by a different approach of normalization using diffpairs which was described earlier in ref. 43.

The 9-miR model as described by Matthaei et al. was derived from high throughput analysis of 11 cyst fluid samples and subsequently validated using singleplex quantitative reverse transcription-polymerase chain reaction (PCR) in 37 cyst fluid samples. In the validation cohort a threshold of 50% yielded a sensitivity of 89% and specificity of 100%.22 In our study, we performed an external validation of the use of this model and observe a significant difference in predicted risk of low risk and high risk cysts. Despite this difference, the proposed cut-off value of 50% yielded a sensitivity of only 10% and specificity of 100.0%. While our study showed a diagnostic accuracy of 85.5%, we feel this may be biased by the low numbers of high risk cysts in our cohort. In addition, with the sensitivity differing so much between these studies, further validation in other cohorts is warranted before any clinical implementation may be considered. Employing various other cut-off values improved diagnostic accuracy to levels that are theoretically suitable for clinical implementation, however, this is most likely due to overfitting of our study population and lacks generalizability. Even though miRs have been studied for a couple of decades in particular for applicability in the field of cancer, only few have made it into clinical trials, and even less are being used in the clinic despite initial promising results.44 For a biomarker to be implemented in routine clinical care, reproducibility across different hospitals or laboratories must be shown, making this study important for the validation of the 9-miR model in pancreatic cyst fluid.45

This study has several limitations. First, as pancreatic cyst fluid is only collected from a lesion requiring a EUS-FNA,
the study group suffers from a selection bias. However, we believe that this is exactly the population that is most likely to benefit from a molecular marker considering the poor diagnostic yield of cytology in itself.\(^2\) Second, validation of disease by the golden standard of histology was not performed in all patients in our cohort. This is potentially problematic, as the current guidelines are not 100% accurate in predicting malignancy. However, we have previously shown that classification of PCN was >95% accurate in our tertiary referral center. Furthermore, excluding patients without histological confirmation, while improving the sensitivity slightly, still did not result in the clear discrimination as reported by Matthaei \textit{et al.}\(^3\) Third, patients with a small cyst which cannot be reached with an EUS-FNA will not benefit from a biomarker based on cyst fluid, however this holds true for most biomarker studies in pancreatic cyst fluid unless the use of secretin is considered.\(^4\) Prospective studies to follow the natural development of these small asymptomatic lesions are needed.

MiRs can be rapidly and efficiently isolated from pancreatic cyst fluid, making them ideal biomarkers for monitoring dysplastic changes within the cyst. However, in our study, we were unable to replicate the diagnostic characteristics of a promising 9-miR model in pancreatic cyst fluid. More studies are needed to find the holy biomarker grail in pancreatic cyst fluid, whether it be DNA-based, (micro)RNA-based, or protein-based.

**Conclusions**

With cystic lesions ever more frequently found in the pancreas, there is a pressing need for an objective marker to aid the management of pancreatic cysts. Here, we validated a 9-miR panel that has shown great promise in the discrimination between low and high risk cysts. In our study, while observing a significant difference between the two groups, the diagnostic characteristics corresponding to various cut-off values were poor. Thus, the clinical implementation of this biomarker panel is as yet unlikely to be beneficial in the management of pancreatic cysts.

**Materials and methods**

**Pancreatic cyst fluid acquirement.** From January 2009 to October 2013 all patients analyzed for a pancreatic cyst, who subsequently underwent EUS-FNA were included. This study received approval of the Institutional Review Board (MEC-2008–233 and MEC-2012–107). A declaration of Helsinki protocols was followed and all patients provided written informed consent. The pancreatic cyst fluid was stored sterile at −80°C until analysis.

The primary objective of the study was the validation of the 9-miR panel for the prediction of a low risk or high risk cyst.

Low risk cysts consist of cystic lesions without dysplasia, low grade dysplasia and moderate grade dysplasia of which follow-up is indicated. Low risk cysts were defined as no dysplasia, low grade dysplasia or moderate dysplasia. High risk cysts were defined as cystic lesions with high grade dysplasia or invasive carcinoma, which should be resected. The risk classification of PCN occurred based on histopathology, or updated Sendai guidelines when histopathological data was unavailable.

**Total MiR isolation.** Total miR was isolated from pancreatic cyst fluid using the Taqman miRNA ABC Purification Kit—Human Panel A (Applied Biosystems, Glasgow, UK), according to the manufacturer’s protocol. In short, lysates were prepared from pancreatic cyst fluid and subsequently transferred to tubes containing anti-miRNA Dynabeads. These are superparamagnetic beads bound to a set of 377 anti-miRNA oligonucleotides. As a positive control and measure for isolation efficiency, the samples were spiked with 1 nmol/l of non-human cel-miR-39 prior to isolation. After hybridization, the beads were washed and the miRs were eluted in 100 µl elution buffer from aforementioned purification kit.

**cDNA synthesis.** Taqman MicroRNA Reverse Transcription Kit (Applied Biosystems) was used to convert the selected miRs into cDNA according to the manufacturer’s protocol. A total volume of 15 µl (11.25 µl miRNA RT mix + 3.75 µl miRNA sample) was used for the RT reaction. Samples were incubated at 16°C for 30 minutes, 42°C for 30 minutes, 85°C for 5 minutes, and kept at 4°C using the StepOnePlus Real-Time PCR System (Life Technologies, Carlsbad, CA).

**MiR expression analysis by quantitative reverse transcriptase-PCR.** The reverse transcription (RT) product from the cDNA synthesis step was used in a singleplex Taqman MicroRNA Assay reaction according to the manufacturer’s protocol. In short, 18 µl of the Taqman PCR mix was mixed with 2 µl of the RT reaction solution obtained from the RT step. The PCR was run at 95°C for 10 minutes, 95°C for 15 seconds, and 60°C for 60 seconds for 40 cycles using the StepOnePlus Real-Time PCR System (Life Technologies). MiR expression levels were measured in duplicate.

**Selected miRs.** We measured the expression levels of miR18a, miR24, miR30a-3p, miR92a, miR99b, miR106b, miR142-3p, miR342-3p, and miR532-3p as previously reported.\(^2\)

**Statistical analysis**

**Exclusion.** Samples were excluded when the diagnosis was inconclusive, or when there were technical problems with the miR isolation procedure such as clumping of beads.
Furthermore, samples that showed cel-miR39 expression of Ct values above 30 were excluded, as these present samples in which the RNA isolation was inefficient. Of the remaining samples, individual quantitative PCR measurements of miRNAs were excluded when duplicates showed large deviations. Large deviations of duplicates were defined as duplicates that differed >1.96 times the SD of the miR measured in the whole cohort. When both Ct values were >35, deviation correction was not applied due to the imprecision in detection of such low concentrations of the miR.

Diffpairs, risk score, and logistic regression. The generation of diffpairs was performed for normalization of the pancreatic cyst fluid as described elsewhere.43 The nine individual miRNAs measured were combined into seven pairs, the so-called “diffpairs”, as defined by Matthei et al. Diffpair values were generated by subtracting normalized Ct values of the two miRs in that pair (e.g., diffpair (miR18;miR92a) was generated by subtracting Ct(miR18) – Ct(miR92a)). The values obtained from these diffpairs were used to generate a risk score based on published regression coefficients, and subsequently entered in a logistic regression model to generate a score between 0 and 100%.22 Differences between the scores of low risk cysts and high risk cysts were tested by the Mann-Whitney U-test. A P-value of < 0.05 was considered statistically significant. The diagnostic performance of high risk cysts of this model was analyzed with a receiver operator characteristic curve. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were calculated using various cut-off values of the model. The optimal cut-off value was determined using a sensitivity and specificity curve, and confirmed using the freely available online tool “Cutoff Finder”.47

Supplementary material

Figure S1. Ct values of spiked C. elegans miR-39. Samples that showed cel-miR39 expression of Ct values above 30 were excluded, as these present samples in which the RNA isolation was inefficient.

Figure S2. Graph depicting the predicted probability for resection.

Table S1. Table showing the p-value of a Mann-Whitney U-test comparing all possible diffpair combinations between low and high risk cysts.

Table S2. Regression coefficients used in the logistic regression model, adapted from Mattaei et al.

Acknowledgments G.M.F. is financially supported by the Dutch Cancer Society (EMCR 2010-4737). M.P. P. is supported by NWO-ALW (840.12.001) and a personal ECCO grant. The authors state that there are no potential conflicts of interest.

1. Wu, BU, Sampath, K, Berberian, CE, Kwok, KK, Lim, BS, Kao, KT et al. (2014). Prediction of malignancy in cystic neoplasms of the pancreas: a population-based cohort study. Am J Gastroenterol 109: 121–9; quiz 130.
2. de Jong, K, No, CY, Hemans, JJ, Dilgkraat, MG, Gouma, DJ, van Eijck, CH et al. (2010). High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol 8: 806–811.
3. Fernández-del Castillio, C, Targarona, J, Thayer, SP, Rattner, DW, Brugg, WR and Warshaw, AL (2003). Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 138: 427–3; discussion 433.
4. Tanaka, M, Chari, S, Adsad, V, Fernandez-del Castillio, C, Falconi, M, Shinzu, M et al.; International Association of Pancreatology, (2008). International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6: 17–32.
5. Nagai, K, Doi, R, Itto, T, Koda, A, Kozumi, M, Masai, T et al. (2009). Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg 16: 353–358.
6. Tanaka, M, Fernández-del Castillio, C, Adsad, V, Chari, S, Falconi, M, Jang, JY et al.; International Association of Pancreatology. (2012). International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreato 12: 183–197.
7. Goh, BK, Tan, DM, Thng, CH, Lee, SY, Low, AS, Chan, CY et al. (2014). Are the Sendai and Fukushima consensus guidelines for cystic mucinous neoplasms of the pancreas useful in the initial triage of all suspected pancreatic cystic neoplasms? A single-institution experience with 317 surgically-treated patients. Ann Surg Oncol 21: 1919–1926.
8. Utkon, W, Braat, H, Bruno, MJ, van Eijck, CH, Groot Koerkamp, B, Krak, NC et al. (2015). Cytopathological analysis of cyst fluid enhances diagnostic accuracy of mucinous pancreatic cystic neoplasms. Medicine (Baltimore) 94: e688.
9. Brugge, WR, Lewandrowski, K, Lee-Lewandrowski, E, Centeno, BA, Szydlo, T, Regan, S et al. (2004). Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterol 126: 1333–1336.
10. Nagula, S, Kennedy, T, Schatter, MA, Brennan, MF, Gerdes, H, Markowitz, AJ et al. (2010). Evaluation of cyst fluid CEA analysis in the diagnosis of mucinous cysts of the pancreas. J Gastroenterol Surg 14: 1997–2003.
11. Czegzler, S, Turner, BG, Turner, B, Blige, AP, Karaca, C, Pitman, MB et al. (2011). Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas 40: 1024–1028.
12. Szczech, CL, Masecarenhas, RC and O’Kane, DJ (2009). Use of cyst fluid CEA, CA19-9, and amylase for evaluation of pancreatic lesions. Clin Biochem 42: 1585–1588.
13. Gnocchiette, KS and Sinwarden, AK (2007). Systematic review of carbohydrate antigen (CA) 19-9 as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Gastroon 33: 266–270.
14. Khalid, A, Zahid, M, Finkelstein, SD, LeBlanc, JK, Kausnik, N, Ahmad, N et al. (2009). Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastroenterol Endosc 69: 1095–1102.
15. de Bisschop, D, Visani, M, Baccarin, P, Poliemo, AM, Maimone, A, Fornelli, A et al. (2011). Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. PLoS One 6:e87651.
16. Amato, E, Molin, MD, Mafficini, A, Y, J, Malleo, G, Rusev, B et al. (2014). Targeted next-generation sequencing of cancer genes detects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 233: 217–227.
17. Springer, S, Wang, Y, Molin, MD, Masica, DL, Jiao, Y, Kinde, I et al. (2015). A Combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterol 149: 1501–1510.
18. Barat, DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
19. Bartels, CL and Tsongalis, GJ (2009). MicroRNAs: novel biomarkers for human cancer. Clin Chem 55: 623–631.
20. Weber, JA, Baster, DH, Zhang, S, Huang, DY, Huang, HK, Lee, MJ et al. (2010). The microRNA-spectrum in 12 body fluids. Clin Chem 56: 1713–1714.
21. Mitchell, PS, Parkin, RK, Koth, EM, Fritz, BR, Wyman, SK, Pogosova-Agadjanyan, EL et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513–10518.
22. Matthaei, H, Wylie, D, Lloyd, MB, Dal Molin, M, Kemapain, J, Mayo, SC et al. (2012). miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res 18: 4713–4724.
23. Vege, SS, Ziring, B, Jain, R and Moayyedi, P; Clinical Guidelines Committee; American College of Gastroenterology (2015). American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterol 148: 819–22; quiz 12.
24. Moayyedi, P, Weinberg, DS, Schönherr, H and Chak, A (2015). Management of pancreatic cysts in an evidence-based world. Gastroenterol 148: 692–695.
25. Fernández-Del Castillo, C and Tanaka, M (2015). Management of pancreatic cysts: the evidence is not here yet. Gastroenterol 148: 685–687.
26. Cento, M and Hruban, RH (2015). Managing pancreatic cysts: less is more? Gastroenterol 148: 688–691.
27. Bouchie, A (2013). First microRNA mimic enters clinic. Nat Biotechnol 31: 577.
28. Lu, J, Getz, G, Miska, EA, Alvarez-Saavedra, E, Lamb, J, Peck, D et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435: 834–838.
29. Ross, SA and Davis, CD (2014). The emerging role of microRNAs and nutrition in modulating health and disease. Annu Rev Nutr 34: 305–338.
30. Skalsky, RL and Cullen, BR (2010). Viruses, microRNAs, and host interactions. Annu Rev Microbiol 64: 123–141.

Validation of a 9-microRNA Panel in Pancreatic Cysts

Utomo et al.

www.moleculartherapy.org/mtna
31. Grasedieck, S, Sorentino, A, Langer, C, Buske, C, Döhner, H, Mertens, D et al. (2013). Circulating microRNAs in hematological diseases: principles, challenges, and perspectives. Blood 121: 4977–4984.
32. Liu, J, Gao, J, Du, Y, Li, Z, Ren, Y, Gu, J et al. (2012). Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131: 683–691.
33. Schultz, NA, Dehler, C, Jensen, BV, Bjerringaard, JK, Nielsen, KR, Bojesen, SE et al. (2014). MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 311: 392–402.
34. Bauer, AS, Keller, A, Costello, E, Greenhalf, W, Bier, M, Borries, A et al. (2012). Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS One 7: e34151.
35. Jarry, J, Schaden, D, Greenwood, C, Spatz, A and van Kempen, LC (2014). The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol Oncol 8: 819–829.
36. Li, A, Yu, J, Kim, H, Wolfgang, CL, Canto, MI, Hruban, RH et al. (2013). MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 19: 3600–3610.
37. Habbe, N, Koorstra, JB, Mendell, JT, Otterhaus, GJ, Ryu, JK, Feldmann, G et al. (2009). MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 8: 340–346.
38. Ryu, JK, Matthaei, H, Da Molin, M, Hong, SM, Canto, MI, Schulick, RD et al. (2011). Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreas 41: 343–350.
39. Raiter, N, Mayer, HA, Jung, M, Mollenkopf, HJ, Wagner, I, Miller, K et al. (2012). Reference miRNAs for miRNAome analysis of urothelial carcinomas. PLoS One 7: e39309.
40. Han, H, Jo, Y, Lee, J, Choi, S, Jeong, Y, Yun, J, et al. (2014). Identification of suitable reference genes for the relative quantification of microRNAs in pleural effusion. Oncol Lett 7: 1889–1895.
41. Chang, KH, Mestdagh, P, Vandesompele, J, Kerin, MJ and Miller, N (2010). MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 10: 173.
42. Song, J, Bai, Z, Han, W, Zhang, J, Meng, H, Bi, J et al. (2012). Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci 57: 897–904.
43. Szafranska, AE, Davison, TS, John, J, Cannon, T, Sipos, B, Maghnouj, A et al. (2007). MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26: 4442–4452.
44. Nana-Sinkam, SP and Croce, CM (2013). Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93: 98–104.
45. Henry, NL and Hayes, DF (2012). Cancer biomarkers. Mol Oncol 6: 140–146.
46. Kanda, M, Knight, S, Topazian, M, Syngal, S, Farrell, J, Lee, J et al. (2013). Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 62: 1024–1033.
47. Budczies, J, Klauschen, F, Sinn, BV, Gyorffy, B, Schmitt, WD, Darb-Esfahani, S et al. (2012). Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 7: e51862.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

© The Author(s) (2016)

Supplementary Information accompanies this paper on the Molecular Therapy—Nucleic Acids website (http://www.nature.com/mtna)